多靶点酪氨酸激酶抑制剂瑞戈非尼的中国专利技术分析  

Chinese patent analysis of multi⁃target tyrosine kinase inhibitor regorafenib

作　　者：洪梦实 李友 HONG Meng-shi;LI You(Patent Examination Cooperation(Beijing)Center of the Patent Office,CNIPA,Beijing 100160,China)

机构地区：[1]国家知识产权局专利局专利审查协作北京中心,北京100160

出　　处：《中国新药杂志》2023年第23期2385-2393,共9页Chinese Journal of New Drugs

摘　　要：分子靶向治疗是近年来肿瘤治疗领域的研究热点。瑞戈非尼是拜耳公司开发的一款多靶点酪氨酸激酶抑制剂类抗肿瘤药物,已于2017年3月在我国批准上市。本文介绍了瑞戈非尼相关中国专利申请状况,并重点对瑞戈非尼的中国专利技术发展脉络进行了梳理和分析,以期为我国相关制药企业开展相关研究和专利布局提供参考。Molecular targeted therapy has become a research hotspot in the field of cancer therapy in recent years.Regorafenib belongs to the multi⁃target tyrosine kinase inhibitor class of antitumor drug developed by Bayer company,which was approved by NMPA in March 2017.This article introduces the status of regorafenib⁃related Chinese patent applications and focuses on combing and analyzing the development context of patent technology,in order to provide reference for the drug R&D and patent portfolio for relevant domestic pharmaceutical companies.

关 键 词：瑞戈非尼 酪氨酸激酶 肿瘤 专利布局 专利分析 

分 类 号：R95[医药卫生—药学]